
SXTP Stock Forecast & Price Target
SXTP Analyst Ratings
Bulls say
60 Degrees Pharmaceuticals Inc has demonstrated impressive financial growth, with net product revenues increasing by 140% to $607.6k in FY24 and showing a 223% year-over-year rise in Q3 FY25. The continued growth in ARAKODA deliveries, up 14% from the previous year, highlights a strong demand for the product and indicates ongoing sales momentum. Additionally, the favorable safety profile of tafenoquine suggests potential for expanded clinical applications, offering further opportunities for revenue growth and diversification in the company's product lineup.
Bears say
60 Degrees Pharmaceuticals Inc faces significant challenges that contribute to a negative outlook on its stock. The firm reported a sequential decline in product revenues to $100,000 due to supply constraints, despite gaining some offset from Australian research grant revenue, indicating instability in core product performance. Furthermore, the reported gross loss of approximately $9,000, due to a one-time inventory write-off, in combination with low visibility on regulatory approvals and potential dilution from financing, raises substantial concerns about the company’s financial health and future profitability.
This aggregate rating is based on analysts' research of 60 Degrees Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
SXTP Analyst Forecast & Price Prediction
Start investing in SXTP
Order type
Buy in
Order amount
Est. shares
0 shares